The first targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses, conclude investigators of the pivotal trial that led to the drug's approval. Responses were seen in all patients regardless of how many previous drugs they had been treated...
First Drug for MET+ NSCLC Shows High Response Rates
Roxanne Nelson | Medical News | 03 September 2020
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.Create a Free Account I have an account